Background: Many clinical factors can contribute to the efficacy of medical therapy in Inflammatory Bowel Disease (IBD). We assessed their effects on the efficacy of vedolizumab therapy in a cohort of patients with IBD. Methods: We conducted a retrospective study on patients between 18 and 80...
From the paper:
Our retrospective study of patients on vedolizumab therapy for both UC and CD found that higher pre-treatment vitamin D levels were associated with higher endoscopic improvement in UC and greater nutritional and supplementation improvements in iron saturation and B12 levels in CD. Those with higher vitamin D levels had higher vedolizumab drug levels in the CD population. In our CD patients, greater improvement in vitamin D levels correlated with lower CRP levels. This study suggests that vitamin D can play a role in clinical and endoscopic outcomes and should be assessed routinely and optimized in patients with IBD in a prospective study.